Our multitarget stool DNA test (Cologuard) was developed using the principles of biology, chemistry and molecular biology. As a result, it is a powerful combination of technologies packaged into one convenient and highly effective precancer and cancer screening test.
In creating a stool DNA-based test, we sought to incorporate the most discriminating and informative biomarkers to ensure the highest possible sensitivity in detecting colorectal cancer. That is why the test includes a protein biomarker (hemoglobin), 7 distinct DNA point mutation biomarkers (KRAS gene), and 2 different DNA methylation biomarkers (NDRG4 and BMP3). One additional DNA biomarker (beta actin gene) confirms that the appropriate amount of stool DNA is analyzed in each individual sample. This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform.